^
Association details:
| Biomarker: | FLT3 mutation + MLL mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Ninlaro (ixazomib) (Proteasome inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia
Published date:
06/23/2020
Excerpt:
Similar experiments were carried out on cell lines MV411 (Flt3ITD/MLL), THP-1 and OCI-AML3 (both NRAS)...mFLT-3 samples with co-mutations in DNMT3A, NPM1 or tMLL were very sensitive to TAK-659 (IC50 <75 nM) but much less sensitive to Ixazomib alone (IC50>100nM)...We also observed sensitivity to Ixazomib in THP-1 and OCI-AML3, while MV4-11 was sensitive to TAK-659 but relatively resistant to Ixazomib alone.
DOI:
10.1158/1538-7445.AM2020-800
